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P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITORPlatelet Reactivity Is Preferred
Over Genotyping in Monitoring
Efﬁcacy of Antiplatelet Therapy
We read with great interest the report by Viviani Anselmi et al. (1)
on the predictability of platelet reactivity as compared with gene
polymorphism in patients undergoing elective percutaneous coro-
nary intervention (PCI). The authors conclude that CYP2C19
metabolizer status independently predicts major adverse cardiac
events, whereas platelet reactivity is only an independent predictor
in high-risk patients.
Notwithstanding the well-performed and large study (1), we
are puzzled by these results. Because the underlying hypothesis
of the present study is that an inferior response to thienopyr-
idines is associated with (recurrent) ischemic events, the question
is whether genotyping or phenotyping is preferred in identifying
patients at risk. Phenotyping (platelet reactivity as assessed by
the VerifyNow cartridge [Accumetrics, San Diego, California])
has been explored in a large number of observational studies as
well as in the pharmacodynamics analyses of several randomized
clinical trials. In contrast to the ﬁndings of the present study, the
bulk of these data support the supposition that among patients
undergoing PCI treated with clopidogrel or prasugrel, higher
values of platelet reactivity units are associated with ischemic
events (2,3). In addition, platelet reactivity as assessed by the
VerifyNow test is correlated with the active metabolite of clo-
pidogrel (4). Furthermore, in the POPular (Do Platelet Function
Assays Predict Clinical Outcomes in clopidogrel pretreated pa-
tients undergoing elective PCI) (the POPular Study) (2), a sig-
niﬁcant correlation between (high) on-treatment platelet reactivity
and CYP2C19 metabolizer status has been established (5). This is
in line with a large meta-analysis on CYP2C19 genotyping and
outcome in clopidogrel-treated patients, which demonstrated an
association between CYP2C19 genotype and on-treatment platelet
reactivity but lacked proof of a signiﬁcant association of genotype
with cardiovascular events (6). An argument in favor of genotyping
is that it is stable over time, whereas platelet reactivity is not,
because it is inﬂuenced by multiple clinical determinants as well as
laboratory parameters and comedication (7). As a result of variable
baseline platelet reactivity, a response that is stable over time and
equal among individuals can result in a broad range of on-treatment
platelet reactivity levels (8). Therefore, we consider monitoring
platelet reactivity a more appropriate approach of monitoring anti-
platelet therapy.
The results of the current study point precisely in the opposite
direction, and we are curious how the authors explain these dif-
ferences and what their ﬁndings imply for daily clinical practice.
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Reply
Platelet Reactivity Is Preferred Over Genotyping
in Monitoring Efﬁcacy of Antiplatelet Therapy
We thank Drs. Breet and ten Berg for their interest in our paper
(1). When we designed our study, we aimed to conﬁrm and expand
previous observations demonstrating the clinical usefulness of clo-
pidogrel-pathway genotyping and on-treatment platelet residual
(OTR) testing in predicting major adverse cardiac events (MACE)
in patients with stable coronary artery disease (CAD) receiving
drug-eluting stents (DES) and under dual antiplatelet (clopidogrel
plus aspirin) therapy. Our results conﬁrmed that CYP2C19
metabolizer status is an independent predictor of MACE after
DES implantation and can be used for prognostication in all stable
CAD patients. In contrast, high OTR, as assessed with the
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449VerifyNow P2Y12 test (Accumetrics, San Diego, California), has a
clinically relevant role only in high-risk subsets (i.e., patients with
diabetes mellitus [DM] or chronic kidney disease [CKD].
We would like to stress the following issues:
1. The majority of previous positive studies included patients
with acute coronary syndromes, whereas our target population
included only patients with stable CAD. When dealing with
stable CAD patients, with an expected overall low MACE
rate, the assessment of OTR is unlikely to have any prognostic
value due to modest sensitivity and speciﬁcity. On the con-
trary, when dealing with a high-risk population (including
stable patients with DM and/or CKD and patients with acute
coronary syndrome), OTR assessment may have a relevant
clinical beneﬁt (2–6). This may explain why, for example, in
the ADAPT-DES (Assessment of Dual Antiplatelet Therapy
with Drug-Eluting Stents) trial, the OTR (assessed with the
VerifyNow P2Y12 test) was a strong independent predictor of
stent thrombosis at 30 days only in patients with acute cor-
onary syndromes, but not in patients with stable CAD (7).
This result has been also conﬁrmed by Park et al. (8).
2. The POPULAR (Do Platelet Function Assays Predict
Clinical Outcomes in Clopidogrel-Pretreated Patients
Undergoing Elective PCI) trial demonstrated a modest
accuracy of 4 platelet reactivity tests (including the Ver-
ifyNow P2Y12 Test) in predicting clinical outcome (9).
Possible explanations for the discrepancy between our study
and the POPULAR trial are: differences in the risk at
baseline of the patient populations (as suggested by the
different rates of DM, CKD, and bifurcation lesions) and
differences in the type of stent implanted in the 2 studies.
Indeed, in our study, the extensive use of second-generation
DES may have had a relevant role in reducing the MACE
rate at follow-up (10).
3. Finally, our interpretation may also explain the negative
ﬁndings of some recent trials aiming at demonstrating a
clinically-relevant effect of antiplatelet therapy tailored to the
OTR result: neither the strategy of increasing clopidogrel
maintenance dose (GRAVITAS [Gauging Responsiveness
With A VerifyNow Assay-Impact On Thrombosis And
Safety]) or of switching to prasugrel (Trigger PCI and
ARCTIC [Assessment by a Double Randomization of a
Conventional Antiplatelet Strategy Versus a Monitoring-
Guided Strategy for Drug-Eluting Stent Implantation and,
of Treatment Interruption Versus Continuation One Year
After Stenting]) improved the clinical outcome of patients
with high OTR.
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